FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2594-2595 December 14, 2006 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Sharpe, A. H.

To the Editor: In their Perspective article, Sharpe and Abbas (Sept. 7 issue)¹ discuss possible explanations for the adverse events associated with a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412, as reported by Suntharalingam et al.² Sharpe and Abbas suggest that a difference in affinity for CD28 between species may be important.¹ However, an alternative explanation relates to differences in Fc-receptor binding between species, which is dependent on the isotype of the monoclonal antibody.³ It is for this reason that anti-CD3 monoclonal antibodies (signal 1) have been engineered to reduce Fc-receptor binding. This process results in less cross-linking . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.